You just read:

European Commission Approves Astellas' XOSPATA™ (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

News provided by

Astellas Pharma Inc.

Oct 25, 2019, 03:00 ET